Compare BioNano Genomics Inc (BNGO) vs Freeport-McMoRan Inc (FCX) Price & Performance

BNGO trades at $1.18, down 0.84% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company shows improving financial trends, with net losses narrowing significantly from -$232M in 2023 to -$26M in 2025, and recent earnings beats. Revenue remains steady around $29M, while analyst sentiment is positive with 57% buy ratings.

Outlook: BNGO presents a speculative opportunity with strong analyst support and improving fundamentals, but risks include persistent negative cash flows, high operating costs, and competitive pressures in genomics. The stock's low valuation multiples may attract value investors, yet profitability remains a key hurdle.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.